Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$1.2588
−$0.0612 · -4.64%
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Regular session
$1.2588
−$0.0612 · -4.64%
Regular session · ET · Market data may be delayed.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Day range
Current $1.2588
52-week range
Current $1.2588
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
63
Undervalued
Sentiment
52
Mixed
Risk
67
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Day range
Current $1.2588
52-week range
Current $1.2588
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 563.03M USD | 482.04M USD | 433.14M USD | 450.89M USD | 467.36M USD |
| Cost of goods sold | 137.52M USD | 115.74M USD | 106.48M USD | 105.02M USD | 114.2M USD |
| Gross profit | 425.51M USD | 366.3M USD | 326.66M USD | 345.87M USD | 353.16M USD |
| Research and development | 44.54M USD | 50.27M USD | 44.38M USD | 39.76M USD | 30.74M USD |
| Selling, general, and administrative | 326.24M USD | 294.51M USD | 269.75M USD | 283.81M USD | 250.2M USD |
| Operating expenses | 369.64M USD | 367.59M USD | 314.13M USD | 323.57M USD | 280.94M USD |
| Interest income | 2.28M USD | — | — | — | — |
| Interest expense | — | 1.54M USD | 2.19M USD | 2.01M USD | 7.24M USD |
| Depreciation and amortization | 26.94M USD | 17.03M USD | 23.45M USD | 18.03M USD | 16.68M USD |
| Operating income | 55.87M USD | −1.28M USD | 12.53M USD | 22.3M USD | 72.22M USD |
| Net income | 37.03M USD | 861K USD | 4.95M USD | 15.53M USD | 94.2M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.50
98.60% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.43M0.00%2.3T USD0.03%$379.8-0.32%
iShares Russell 2000 ETFIWM2.43M0.00%78.56B USD0.19%$275.4-0.83%
Vanguard Extended Market ETFVXF1.53M0.00%95.4B USD0.05%$231.96-0.66%
Dimensional - US Targeted Value ETFDFAT773.76K0.00%30B USD0.33%$66.93-0.22%
Vanguard Russell 2000 ETFVTWO681.54K0.00%18B USD0.06%$111.23-0.88%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV628.45K0.00%26.69B USD0.33%$37.755-0.11%
Schwab U.S. Small-Cap ETFSCHA528.12K0.00%21.7B USD0.03%$32.375-0.72%
Vanguard Health Care ETFVHT379.76K0.00%22B USD0.09%$309.04-1.99%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATVanguard Russell 2000 ETFVTWOU.S. Small Cap Value Portfolio ETF Class SharesDFSVSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
